Clinical Trial Update: Venetoclax in Combination With Ivosidenib and Azacitidine for Newly Diagnosed IDH1-Mutated AML [Phase 1, Phase 2]

View source ↗

Summary

This clinical trial update indicates a Phase 1/2 study evaluating venetoclax in combination with ivosidenib and azacitidine for newly diagnosed IDH1-mutated acu…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Acute Myeloid Leukemia

Drugs mentioned

• Tibsovo (ivosidenib)
• VIDAZA (AZACITIDINE)
• Venclexta (venetoclax)

Snippet

Sponsor: Institute of Hematology & Blood Diseases Hospital, China | Conditions: AML, IDH1 Mutation | Phase 1, Phase 2 | Status: RECRUITING